The Use Of Nicotinic Acid In The Treatment Of Heart Disease – Part 3 of 3
Did the fault lie with the laropiprant and not niacin? Armitage is doubtful. She pointed to a prior trial, called AIM-HIGH, which was discontinued initially in 2011 when researchers found no benefit to niacin treatment. At the time, some experts said that the smaller population in AIM-HIGH masked any sign of benefit, but Armitage said the inexperienced trial’s much bigger study group confirms that niacin probably does not help.
Speaking in February 2013 at the time of the journal’s release of niacin’s safety profile, one US expert was less than impressed by niacin’s performance. The suffering “confirms that, for the present moment, there may be little additional benefit with the use of niacin when patients are well treated with the lipid-lowering statin drugs,” said Dr Kevin Marzo, principal of cardiology at Winthrop-University Hospital in Mineola, NY. He said that the results of the new trial, along with those from a prior large study, “now may put the final nail in the coffin on niacin-based strategies to get together HDL and lower cardiovascular events”.
Other tried-and-true approaches may work best. “In addition to statins, our focus should be on continued lifestyle changes such as a Mediterranean diet, complemented with everyday exercise”. The US Food and Drug Administration had been waiting on the new trial results to decide whether to approve niacin/laropiprant for use against heart disease view homepage. But in December 2012, responding to beginning findings, drug maker Merck said it no longer planned to press for approval from the FDA and in January 2013 delayed niacin/laropiprant from markets worldwide.